Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab. Clin Ther. 2025 Aug; 47(8):559-565.
-
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth. J Immunother Cancer. 2024 Dec 22; 12(12).
-
Efficacy and safety of dulaglutide 3.0?and 4.5?mg in patients aged?younger than?65 and?65?years or older: Post hoc analysis of the AWARD-11 trial. Diabetes Obes Metab. 2021 10; 23(10):2279-2288.
-
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29.
-
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood. 2010 Jun 24; 115(25):5241-8.
-
p62 is involved in the mechanism of Mallory body formation. Exp Mol Pathol. 2004 Dec; 77(3):168-75.
-
PAR-1 is required for the maintenance of oocyte fate in Drosophila. Development. 2001 Apr; 128(7):1201-9.
-
Multiple cellular proteins are recognized by the adeno-associated virus Rep78 major regulatory protein and the amino-half of Rep78 is required for many of these interactions. Biochem Mol Biol Int. 1997 Oct; 43(2):409-20.
-
Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol Oncol. 1997 Sep; 66(3):487-94.
-
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A. 1997 May 13; 94(10):5296-301.